PL394601A1 - Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo)-fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego oraz kompozycja farmaceutyczna ją zawierająca - Google Patents

Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo)-fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego oraz kompozycja farmaceutyczna ją zawierająca

Info

Publication number: PL394601A1
Authority: PL; Poland
Prior art keywords: methyl; hexyloxycarbonylaminoiminomethyl; benzimidazol; ylamino; phenylamino
Prior art date: 2002-03-07

Application number

PL394601A

Other languages

English (en)

Other versions

PL212566B1 (pl

Inventor

Ulrich Brauns

Norbert Hauel

Peter Sieger

Original Assignee

Boehringer Ingelheim Pharma Gmbh & Co.Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-07

Filing date

2003-03-03

Publication date

2011-07-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27789735&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL394601(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-07 Priority claimed from DE10209985A external-priority patent/DE10209985A1/de

2002-09-30 Priority claimed from DE2002145624 external-priority patent/DE10245624A1/de

2003-03-03 Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg

2011-07-18 Publication of PL394601A1 publication Critical patent/PL394601A1/pl

2012-10-31 Publication of PL212566B1 publication Critical patent/PL212566B1/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)

PL394601A 2002-03-07 2003-03-03 Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo) fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego PL212566B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10209985A DE10209985A1 (de)	2002-03-07	2002-03-07	Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
DE2002145624 DE10245624A1 (de)	2002-09-30	2002-09-30	Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze

Publications (2)

Publication Number	Publication Date
PL394601A1 true PL394601A1 (pl)	2011-07-18
PL212566B1 PL212566B1 (pl)	2012-10-31

Family

ID=27789735

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL394601A PL212566B1 (pl)	2002-03-07	2003-03-03	Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo) fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego
PL370517A PL210862B1 (pl)	2002-03-07	2003-03-03	Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL370517A PL210862B1 (pl)	2002-03-07	2003-03-03	Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji

Country Status (36)

Country	Link
US (2)	US20190231766A1 (pl)
EP (2)	EP1485094B2 (pl)
JP (3)	JP3866715B2 (pl)
KR (1)	KR101005716B1 (pl)
CN (1)	CN100528157C (pl)
AR (2)	AR042861A1 (pl)
AT (1)	ATE540943T1 (pl)
AU (1)	AU2003210400B8 (pl)
BR (1)	BRPI0306559B8 (pl)
CA (1)	CA2476054C (pl)
CL (1)	CL2009001915A1 (pl)
CO (1)	CO5611149A2 (pl)
CY (4)	CY1112796T1 (pl)
DE (1)	DE122012000047I1 (pl)
DK (2)	DK1485094T4 (pl)
EA (1)	EA009664B1 (pl)
EC (1)	ECSP045331A (pl)
ES (2)	ES2390661T5 (pl)
HK (1)	HK1078792A1 (pl)
HR (1)	HRP20040807B1 (pl)
IL (3)	IL163863A0 (pl)
LU (2)	LU92025I2 (pl)
ME (1)	ME00325B (pl)
MX (1)	MXPA04008542A (pl)
MY (1)	MY143734A (pl)
NO (3)	NO326918B1 (pl)
NZ (2)	NZ546367A (pl)
PE (1)	PE20030889A1 (pl)
PL (2)	PL212566B1 (pl)
PT (2)	PT1870100E (pl)
RS (1)	RS52088B (pl)
SG (1)	SG146435A1 (pl)
SI (2)	SI1870100T1 (pl)
TW (1)	TWI293879B (pl)
WO (1)	WO2003074056A1 (pl)
ZA (1)	ZA200406071B (pl)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030181488A1 (en)	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en)	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) *	2003-08-16	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) *	2003-08-29	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE10341043A1 (de) *	2003-09-03	2005-03-31	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
EP1757310A1 (en) *	2004-05-24	2007-02-28	Qualicaps Co., Ltd.	Surface-modified and solubility-improved hard capsule
DE102004062864A1 (de)	2004-12-21	2006-06-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Folienbehälter
US20060222640A1 (en) *	2005-03-29	2006-10-05	Boehringer Ingelheim International Gmbh	New pharmaceutical compositions for treatment of thrombosis
DE102005025728A1 (de)	2005-06-04	2006-12-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061624A1 (de) *	2005-12-21	2007-06-28	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
DE102005061623A1 (de) *	2005-12-21	2007-06-28	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
CA2657270A1 (en) *	2006-07-17	2008-01-24	Boehringer Ingelheim International Gmbh	New paediatric indications for direct thrombin inhibitors
CA2657266A1 (en) *	2006-07-17	2008-01-24	Boehringer Ingelheim International Gmbh	New indications for direct thrombin inhibitors in the cardiovascular field
JP2010505906A (ja) *	2006-10-10	2010-02-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステルの生理学的に許容される塩
WO2009118321A1 (de) *	2008-03-28	2009-10-01	Boehringer Ingelheim International Gmbh	Verfahren zur herstellung von säurepellets
EP2288335A1 (en) *	2008-03-28	2011-03-02	Boehringer Ingelheim International GmbH	Process for preparing orally administered dabigatran formulations
TWI436994B (zh)	2008-07-14	2014-05-11	Boehringer Ingelheim Int	製備含有達比加群（ｄａｂｉｇａｔｒａｎ）之藥物組合物的新穎方法
JP5295356B2 (ja)	2008-07-28	2013-09-18	武田薬品工業株式会社	医薬組成物
WO2010020600A1 (en) *	2008-08-19	2010-02-25	Boehringer Ingelheim International Gmbh	Use of dabigatranetexilate for treating patients with pulmonary hypertension
MX2011001612A (es) *	2008-08-19	2011-03-04	Boehringer Ingelheim Int	Dabigatran para cateterismo cardiaco con intervencion percutanea.
WO2010130757A1 (en)	2009-05-14	2010-11-18	Boehringer Ingelheim International Gmbh	New combination therapy in treatment of oncological and fibrotic diseases
ES2436076T3 (es)	2009-08-24	2013-12-26	Boehringer Ingelheim International Gmbh	Intervenciones de urgencia de carbón vegetal activo con sobredosificación con etexilato de dabigatrán
JP5801826B2 (ja)	2010-03-01	2015-10-28	ラティオファルムゲー・エム・ベー・ハー	ダビガトランエテキシラートを含有する経口用医薬組成物
US20130149346A1 (en)	2010-03-08	2013-06-13	ratiopharm GmbH Graf-Arco-Strasse 3	Dabigatran etexilate-containing pharmaceutical composition
US20130177652A1 (en)	2010-07-01	2013-07-11	Krka, Tovarna Zdravil, D.D., Novo Mesto	Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
CN102985416B (zh)	2010-07-09	2015-04-01	埃斯特维化学股份有限公司	制备凝血酶特异性抑制剂的方法
WO2012004397A1 (en)	2010-07-09	2012-01-12	Esteve Química, S.A.	Intermediates and process for preparing a thrombin specific inhibitor
HUE026408T2 (en)	2010-09-27	2016-06-28	Ratiopharm Gmbh	Dabigatran etexylate bis-mesylate salt, solid forms and process for their preparation
JP2014517843A (ja) *	2011-05-24	2014-07-24	テバファーマシューティカルインダストリーズリミティド	医薬組成物用の圧縮コア
CN102391250B (zh) *	2011-08-29	2013-06-19	石药集团欧意药业有限公司	一种达比加群酯化合物、制备方法及其药物组合物
CA2860098A1 (en) *	2011-12-22	2013-06-27	Boehringer Ingelheim International Gmbh	Immediate release multi unit pellet system
US9212166B2 (en)	2012-01-20	2015-12-15	Cadila Healthcare Limited	Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
EP2806858A1 (en)	2012-01-24	2014-12-03	Boehringer Ingelheim International Gmbh	Novel orally administered dabigatran formulation
RU2633482C2 (ru)	2012-02-21	2017-10-12	Лабораторьос Дель Др. Эстеве, С.А.	Пероральные фармацевтические композиции дабигатрана этексилата
EP2631234A1 (en)	2012-02-23	2013-08-28	Esteve Química, S.A.	Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en)	2012-03-27	2013-10-03	Cadila Healthcare Limited	New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
US9273030B2 (en)	2012-04-02	2016-03-01	Msn Laboratories Private Limited	Process for the preparation of benzimidazole derivatives and salts thereof
US20130345262A1 (en)	2012-06-25	2013-12-26	Boehringer Ingelheim International Gmbh	Method for prevention of stroke
EP2900651A2 (en)	2012-09-28	2015-08-05	Ranbaxy Laboratories Limited	Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
US20150225370A1 (en)	2012-09-28	2015-08-13	Ranbaxy Laboratories Limited	Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014060561A1 (en)	2012-10-19	2014-04-24	Sanovel Ilac Sanayi Ve Ticaret A.S.	Oral pharmaceutical formulations comprising dabigatran
EP2722033A1 (en)	2012-10-19	2014-04-23	Sanovel Ilac Sanayi ve Ticaret A.S.	Pharmaceutical Compositions of Dabigatran Free Base
EP2740471B1 (en)	2012-12-07	2015-05-27	Hexal AG	Oral pharmaceutical composition comprising dabigatran etexilate
CN103127109B (zh) *	2013-02-05	2014-08-13	南京华威医药科技开发有限公司	含达比加群酯或其盐和水合物的药用组合
EP2835370A1 (en)	2013-08-08	2015-02-11	Medichem, S.A.	New crystals of dabigatran etexilate mesylate
CN104414995A (zh) *	2013-09-04	2015-03-18	天津汉瑞药业有限公司	甲磺酸达比加群酯的药用组合物
EP2853260A1 (en)	2013-09-27	2015-04-01	ratiopharm GmbH	Pharmaceutical preparation comprising dabigatran etexilate bismesylate
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals
IN2014MU01042A (pl)	2014-03-26	2015-10-02	Cadila Healthcare Ltd
EP2933002A1 (en)	2014-04-11	2015-10-21	Sanovel Ilac Sanayi ve Ticaret A.S.	Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155297A1 (en)	2014-04-11	2015-10-15	Sanovel Ilac Sanayi Ve Ticaret A.S.	Pharmaceutical combinations of dabigatran and h2-receptor antagonists
DE102014108210A1 (de)	2014-06-11	2015-12-17	Dietrich Gulba	Rodentizid
US10675276B2 (en)	2014-11-03	2020-06-09	Hangzhou Solipharma Co., Ltd.	Dosing preparation of dabigatran etexilate or a salt thereof and a preparation method thereof
CN105640909B (zh) *	2014-11-14	2019-09-20	正大天晴药业集团股份有限公司	一种含有达比加群酯的药用组合物
CN106924256B (zh) *	2015-12-25	2022-08-19	深圳市药欣生物科技有限公司	药物组合物及其制备方法
EP3251672B1 (en) *	2014-12-31	2023-02-01	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical composition comprising dabigatran etexilate and preparation method therefor
CN105797162B (zh) *	2014-12-31	2022-10-25	昆明积大制药股份有限公司	药用辅料表面改性方法
TR201502223A2 (tr)	2015-02-25	2016-09-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dronedaron ve dabigatranın farmasötik kombinasyonları.
CN106999434B (zh) *	2015-04-08	2020-05-22	杭州领业医药科技有限公司	一种含半胱氨酸盐酸盐的微丸及其制备方法
WO2017013106A1 (en)	2015-07-20	2017-01-26	Sanovel Ilac Sanayi Ve Ticaret A.S.	Pharmaceutical formulations of dabigatran free base
CN105919962B (zh) *	2015-12-18	2019-01-18	重庆两江药物研发中心有限公司	一种达比加群酯片剂及其制备方法
EP3184102A1 (en)	2015-12-23	2017-06-28	Hexal AG	Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
WO2017111637A1 (en)	2015-12-23	2017-06-29	Zaklady Farmaceutyczne Polpharma Sa	Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
US10449195B2 (en)	2016-03-29	2019-10-22	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical formulation of palbociclib and a preparation method thereof
TR201606697A2 (tr)	2016-05-20	2017-12-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dabi̇gatranin yeni̇ oral farmasöti̇k formülasyonlari
WO2018104387A1 (en)	2016-12-07	2018-06-14	Sanovel Ilac Sanayi Ve Ticaret A.S.	Multilayered tablet compositions of dabigatran
TR201617984A2 (tr)	2016-12-07	2018-06-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dabi̇gatranin farmasöti̇k kompozi̇syonlari
EP3342401A1 (en)	2016-12-28	2018-07-04	Sanovel Ilac Sanayi ve Ticaret A.S.	Bilayer tablet formulations of dabigatran etexilate
JP2018184375A (ja)	2017-04-27	2018-11-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
WO2018229784A1 (en) *	2017-06-14	2018-12-20	Natco Pharma Limited	Pharmaceutical compositions of dabigatran
CN109125274A (zh) *	2017-06-28	2019-01-04	上海美悦生物科技发展有限公司	注射用苯并咪唑类药用酸组合物及其制备方法和用途
TR201722186A2 (tr)	2017-12-27	2019-07-22	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dabi̇gatranin farmasöti̇k kompozi̇syonlari
TR201722323A2 (tr)	2017-12-27	2019-07-22	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722353A2 (tr)	2017-12-27	2019-07-22	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dabi̇gatran eteksi̇lat i̇çeren oral uygulama i̇çi̇n farmasöti̇k formülasyon
TR201722630A2 (pl)	2017-12-28	2019-07-22	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
CN110339193B (zh)	2018-04-04	2022-04-29	上海汉都医药科技有限公司	含达比加群酯的药物组合物及其制备方法
KR20200082641A (ko)	2018-12-31	2020-07-08	주식회사 유영제약	다비가트란 에텍실레이트를 포함하는 약제학적 조성물
EP3771465A1 (en)	2019-08-01	2021-02-03	Zaklady Farmaceutyczne Polpharma SA	Pharmaceutical composition comprising dabigatran etexilate
KR20210157691A (ko)	2020-06-22	2021-12-29	한국유나이티드제약 주식회사	다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157692A (ko)	2020-06-22	2021-12-29	한국유나이티드제약 주식회사	다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157693A (ko)	2020-06-22	2021-12-29	한국유나이티드제약 주식회사	다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
CN114306245A (zh)	2020-09-29	2022-04-12	深圳市药欣生物科技有限公司	无定形固体分散体的药物组合物及其制备方法
EP4070658A1 (de)	2021-04-06	2022-10-12	BIORoxx GmbH	Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
CN115227663B (zh) *	2021-04-22	2023-12-12	石药集团恩必普药业有限公司	一种甲磺酸达比加群酯胶囊及其制备方法
WO2023139243A1 (en)	2022-01-21	2023-07-27	Adamed Pharma S.A	A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran
GR1010399B (el) *	2022-04-05	2023-02-03	Φαρματεν Α.Β.Ε.Ε.,	Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιπηκτικο παραγοντα και μεθοδος παραγωγης αυτου

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6087380A (en) *	1949-11-24	2000-07-11	Boehringer Ingelheim Pharma Kg	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE3126703A1 (de) *	1981-07-07	1983-01-27	Dr. Karl Thomae Gmbh, 7950 Biberach	Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) *	1982-02-02	1983-08-10	Fujisawa Pharmaceut Co Ltd	医薬組成物
PE121699A1 (es) *	1997-02-18	1999-12-08	Boehringer Ingelheim Pharma	Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10133786A1 (de) *	2001-07-16	2003-02-06	Boehringer Ingelheim Pharma	Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

2003
- 2003-03-03 AT AT07115663T patent/ATE540943T1/de active
- 2003-03-03 CN CNB038054736A patent/CN100528157C/zh not_active Expired - Lifetime
- 2003-03-03 MX MXPA04008542A patent/MXPA04008542A/es active IP Right Grant
- 2003-03-03 RS YU79204A patent/RS52088B/sr unknown
- 2003-03-03 BR BRPI0306559A patent/BRPI0306559B8/pt not_active IP Right Cessation
- 2003-03-03 EP EP03743368.7A patent/EP1485094B2/de not_active Expired - Lifetime
- 2003-03-03 SI SI200332126T patent/SI1870100T1/sl unknown
- 2003-03-03 EP EP07115663A patent/EP1870100B1/de not_active Revoked
- 2003-03-03 KR KR1020047013919A patent/KR101005716B1/ko active IP Right Review Request
- 2003-03-03 JP JP2003572573A patent/JP3866715B2/ja not_active Expired - Lifetime
- 2003-03-03 DK DK03743368.7T patent/DK1485094T4/da active
- 2003-03-03 PL PL394601A patent/PL212566B1/pl unknown
- 2003-03-03 CA CA2476054A patent/CA2476054C/en not_active Expired - Lifetime
- 2003-03-03 PL PL370517A patent/PL210862B1/pl unknown
- 2003-03-03 ES ES03743368T patent/ES2390661T5/es not_active Expired - Lifetime
- 2003-03-03 SI SI200332190T patent/SI1485094T2/sl unknown
- 2003-03-03 IL IL16386303A patent/IL163863A0/xx unknown
- 2003-03-03 EA EA200401136A patent/EA009664B1/ru unknown
- 2003-03-03 ES ES07115663T patent/ES2380704T3/es not_active Expired - Lifetime
- 2003-03-03 NZ NZ546367A patent/NZ546367A/en not_active IP Right Cessation
- 2003-03-03 AU AU2003210400A patent/AU2003210400B8/en not_active Expired
- 2003-03-03 WO PCT/EP2003/002141 patent/WO2003074056A1/de active Application Filing
- 2003-03-03 DK DK07115663.2T patent/DK1870100T3/da active
- 2003-03-03 ME MEP-2008-507A patent/ME00325B/me unknown
- 2003-03-03 SG SG200504113-2A patent/SG146435A1/en unknown
- 2003-03-03 PT PT07115663T patent/PT1870100E/pt unknown
- 2003-03-03 NZ NZ535663A patent/NZ535663A/en not_active IP Right Cessation
- 2003-03-03 PT PT03743368T patent/PT1485094E/pt unknown
- 2003-03-05 MY MYPI20030780A patent/MY143734A/en unknown
- 2003-03-05 PE PE2003000211A patent/PE20030889A1/es active IP Right Grant
- 2003-03-06 TW TW092105051A patent/TWI293879B/zh active
- 2003-03-07 AR ARP030100779A patent/AR042861A1/es active Pending
2004
- 2004-06-07 NO NO20042361A patent/NO326918B1/no not_active IP Right Cessation
- 2004-07-29 ZA ZA2004/06071A patent/ZA200406071B/en unknown
- 2004-09-01 IL IL163863A patent/IL163863A/en active IP Right Review Request
- 2004-09-06 HR HRP20040807AA patent/HRP20040807B1/hr not_active IP Right Cessation
- 2004-09-30 EC EC2004005331A patent/ECSP045331A/es unknown
- 2004-10-06 CO CO04099830A patent/CO5611149A2/es active IP Right Grant
2005
- 2005-12-01 HK HK05110948.7A patent/HK1078792A1/xx not_active IP Right Cessation
2006
- 2006-08-10 JP JP2006218435A patent/JP2007056018A/ja active Pending
- 2006-08-10 JP JP2006218436A patent/JP4953727B2/ja not_active Expired - Lifetime
2008
- 2008-03-12 NO NO20081304A patent/NO332209B1/no not_active IP Right Cessation
2009
- 2009-06-26 AR ARP090102391A patent/AR072385A2/es active Pending
- 2009-09-29 CL CL2009001915A patent/CL2009001915A1/es unknown
2010
- 2010-11-17 IL IL209368A patent/IL209368A/en active IP Right Grant
2012
- 2012-04-09 CY CY20121100346T patent/CY1112796T1/el unknown
- 2012-06-20 LU LU92025C patent/LU92025I2/fr unknown
- 2012-06-29 DE DE201212000047 patent/DE122012000047I1/de active Pending
- 2012-07-10 CY CY2012020C patent/CY2012020I1/el unknown
- 2012-09-28 CY CY20121100894T patent/CY1113158T1/el unknown
- 2012-12-14 CY CY2012031C patent/CY2012031I2/el unknown
- 2012-12-19 LU LU92117C patent/LU92117I2/fr unknown
2013
- 2013-01-02 NO NO2013001C patent/NO2013001I2/no not_active Application Discontinuation
2019
- 2019-04-10 US US16/380,161 patent/US20190231766A1/en not_active Abandoned
- 2019-11-25 US US16/694,091 patent/US20200085807A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP3866715B2 (ja)	2007-01-10
DK1485094T4 (da)	2020-06-22
NO326918B1 (no)	2009-03-16
EP1870100A1 (de)	2007-12-26
CL2009001915A1 (es)	2010-02-12
KR101005716B1 (ko)	2011-01-05
ES2380704T3 (es)	2012-05-17
HRP20040807B1 (hr)	2014-11-21
DE122012000047I1 (de)	2012-09-13
EA009664B1 (ru)	2008-02-28
CO5611149A2 (es)	2006-02-28
MXPA04008542A (es)	2004-12-06
IL163863A (en)	2013-02-28
BRPI0306559B8 (pt)	2021-05-25
LU92025I2 (fr)	2012-08-20
ES2390661T3 (es)	2012-11-15
WO2003074056A1 (de)	2003-09-12
ES2380704T9 (es)	2013-07-24
DK1870100T3 (da)	2012-05-14
AU2003210400A1 (en)	2003-09-16
AR042861A1 (es)	2005-07-06
IL209368A0 (en)	2011-01-31
NO2013001I1 (no)	2013-02-11
CA2476054A1 (en)	2003-09-12
RS79204A (en)	2007-02-05
CY1112796T1 (el)	2015-08-05
PL370517A1 (pl)	2005-05-30
CY2012020I2 (el)	2015-08-05
BR0306559A (pt)	2004-11-30
ECSP045331A (es)	2006-04-19
AU2003210400B2 (en)	2008-08-07
SG146435A1 (en)	2008-10-30
CN1638771A (zh)	2005-07-13
CA2476054C (en)	2011-11-08
PT1870100E (pt)	2012-04-17
NO20042361D0 (no)	2004-06-07
SI1485094T2 (sl)	2020-08-31
CY1113158T1 (el)	2015-08-05
CY2012031I1 (el)	2015-08-05
JP2005519099A (ja)	2005-06-30
EA200401136A1 (ru)	2005-04-28
US20190231766A1 (en)	2019-08-01
LU92117I2 (fr)	2013-02-19
MEP50708A (en)	2011-02-10
AU2003210400B8 (en)	2008-09-25
RS52088B (sr)	2012-06-30
PL212566B1 (pl)	2012-10-31
ZA200406071B (en)	2005-11-30
KR20040099298A (ko)	2004-11-26
IL209368A (en)	2012-10-31
DK1485094T3 (da)	2012-10-15
NO20042361L (no)	2004-06-07
AR072385A2 (es)	2010-08-25
NZ546367A (en)	2008-08-29
JP2006328081A (ja)	2006-12-07
EP1870100B1 (de)	2012-01-11
PT1485094E (pt)	2012-10-09
PE20030889A1 (es)	2003-12-10
ME00325B (me)	2011-05-10
CY2012020I1 (el)	2015-08-05
US20200085807A1 (en)	2020-03-19
CY2012031I2 (el)	2015-08-05
ATE540943T1 (de)	2012-01-15
BRPI0306559B1 (pt)	2021-05-18
TWI293879B (en)	2008-03-01
NO20081304L (no)	2004-06-07
EP1485094A1 (de)	2004-12-15
PL210862B1 (pl)	2012-03-30
NZ535663A (en)	2006-06-30
SI1870100T1 (sl)	2012-05-31
JP4953727B2 (ja)	2012-06-13
HK1078792A1 (en)	2006-03-24
NO332209B1 (no)	2012-07-30
IL163863A0 (en)	2005-12-18
CN100528157C (zh)	2009-08-19
EP1485094B2 (de)	2020-03-25
MY143734A (en)	2011-07-15
JP2007056018A (ja)	2007-03-08
ES2390661T5 (es)	2020-12-04
HRP20040807A2 (en)	2005-02-28
EP1485094B1 (de)	2012-07-04
SI1485094T1 (sl)	2012-10-30
NO2013001I2 (no)	2014-09-01
TW200306188A (en)	2003-11-16

Publication	Publication Date	Title
PL394601A1 (pl)	2011-07-18	Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo)-fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego oraz kompozycja farmaceutyczna ją zawierająca
DK1658056T3 (da)	2008-09-08	Tabletter indeholdende 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionsyreethylester eller salte deraf
IL173885A0 (en)	2006-07-05	3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1- methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament
EP1801096B8 (en)	2017-12-13	Polyglycerol fatty acid ester and composition containing same
HK1100004A1 (en)	2007-08-31	Synthesis of boronic ester and acid compounds
IL172875A0 (en)	2006-06-11	Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
EP1578949A3 (en)	2005-11-10	Site specific incorporation of keto amino acids into proteins
PT1488790E (pt)	2014-10-10	Preparação sólida contendo uma forma de cristal único a de um derivado de ácido tiazolcarboxílico
EP1709952B8 (en)	2013-02-13	Composition containing polyglycerol/medium-chain fatty acid ester
EP1816128A4 (en)	2009-11-18	CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE CYCLE AND PHARMACEUTICAL APPLICATIONS THEREOF
HUP0203444A3 (en)	2003-05-28	Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, process for its preparation, pharmaceutical composition containing it and use thereof
AU2003225651A1 (en)	2003-09-22	Nematicidal fatty acid and fatty acid ester related compounds
TWI339586B (en)	2011-04-01	Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
EP1633328A4 (en)	2008-07-09	METHOD AND COMPOSITION FOR STABLE AND CONTROLLED ADMINISTRATION OF (-) - HYDROXYCITRIC ACID
AU2003282178A1 (en)	2004-04-19	Novel method for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid and application of divalent salts of ranelic acid and the hydrates thereof in said synthesis
AU2003201911A1 (en)	2003-07-24	Method of preventing clogging of apparatus for handling (meth)acrylic acid and ester thereof
AU2003215947A1 (en)	2003-12-31	Controlled release composition comprising felodipine and method of preparation thereof
AU2003224144A1 (en)	2003-11-11	Method for the production of acrylic acid and/or the esters thereof and propionic acid and/or the esters thereof in a compound
ZA200609582B (en)	2008-06-25	Novel compositions comprising higher pimary alcohols and nicotinic acid and process of preparation thereof
IS7056A (is)	2003-11-28	Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3 [4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxý própansýru og insúlín
PL370962A1 (pl)	2005-05-02	Nowe estry etylowe kwasu (2'-izopropenylo-5'-metylo-1'-cykloheksylideno)-octowego i sposób ich otrzymywania
AU2003203174A1 (en)	2003-09-02	Metal salts of (3s)-3-methoxycarbonyl-4-phenylbutyric acid and usage thereof
ITMI20042092A1 (it)	2005-02-02	Metodo per l'allestimento di pareti di ambienti e ambienti cosi' ottenuti
DE60209436D1 (de)	2006-04-27	Alkyl Ester der 2-(2-Fluorosulfonyl)-perfluoroethylenoxy-3-halogen-Propionsäure
GB0415097D0 (en)	2004-08-04	Formulation containing a carboxylic acid or an ester thereof